{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-141699","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.705232+00:00","generated_at":"2026-06-01T15:24:34.044642+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Stockholders approve doubling authorized common stock to 300M shares","bullets":["Charter amendment to increase authorized common stock from 150M to 300M shares approved with 42.7M for, 3.2M against.","Class III directors Ashworth, Meyers, and Gilbert each elected with >24M votes for; broker non-votes of 17.6M.","Ratification of Ernst & Young as auditor for FY2024 passed with 46.5M votes for.","Advisory vote on executive compensation approved with 27.4M for, 1.9M against, 17.6M broker non-votes.","All four stockholder proposals at May 15 Annual Meeting were approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-141699","json":"https://secwatch.observer/filing/0001193125-24-141699.json","markdown":"https://secwatch.observer/filing/0001193125-24-141699.md","text":"https://secwatch.observer/filing/0001193125-24-141699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/d816353d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T15:24:34.044642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd71f4c4745645ec8a00e29463c09ace70e099c4","claim":"CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 shares (effective 2024-05-17).","evidence_excerpt":"On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","confidence":0.9},{"claim_id":"4de2c3da2427848f5ae03ea278bfbf3f4eb886ff","claim":"CytomX Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","confidence":0.98},{"claim_id":"6560b6f50e1918a1913d47fae33dee7b4d160133","claim":"CytomX Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 150,000,000 to 300,000,000 at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 3. The Company’s stockholders approved of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares. FOR AGAINST ABSTAIN 42,707,436 3,211,496 999,741","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","confidence":0.98},{"claim_id":"84007f2377ce107ffbc804776b397b63ec85e053","claim":"CytomX Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. FOR AGAINST ABSTAIN 46,522,474 369,346 26,853","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","confidence":0.98},{"claim_id":"f7ae2ae9044b16d49ab9b3139103b88de15627f5","claim":"CytomX Therapeutics, Inc. shareholders approved Election of Class III directors at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 1. The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Alan Ashworth, Ph.D., FRS 28,770,373 514,091 79,486 17,554,723 James R. Meyers 28,970,141 324,310 69,499 17,554,723 Halley Gilbert 24,008,423 5,271,685 83,842 17,554,723","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-214680","ticker":"BAX","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"Baxter shareholders approve charter amendment and incentive plan; board adopts new executive severance plan","event_type":"other","sec_items":["5.02","5.07","5.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214680","json":"https://secwatch.observer/filing/0001193125-26-214680.json","markdown":"https://secwatch.observer/filing/0001193125-26-214680.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000119312526214680/0001193125-26-214680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000119312526214680/d24051d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"the Board approved a corresponding amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended Bylaws”) reflecting that the number of directors on the Board shall not be less than seven nor more than twelve","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312526214680/0001193125-26-214680-index.htm"}},{"accession":"0001767042-26-000037","ticker":"KGS","company_name":"Kodiak Gas Services, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Kodiak shareholders approve board declassification and supermajority removal","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001767042-26-000037","json":"https://secwatch.observer/filing/0001767042-26-000037.json","markdown":"https://secwatch.observer/filing/0001767042-26-000037.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1767042/000176704226000037/0001767042-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1767042/000176704226000037/kgs-20260507.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"At the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Kodiak Gas Services, Inc. (the “Company”) held on May 7, 2026, the Company’s shareholders approved certain amendments (the “Charter Amendments”) to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to (i) phase in declassification of the Board of Directors (the “Board”) and (ii) eliminate certain supermajority voting requirements and other obsolete provisions.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1767042/000176704226000037/0001767042-26-000037-index.htm"}},{"accession":"0001193125-26-215591","ticker":"PSA","company_name":"Public Storage","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shankh Mitra re-elected as chairman with 24% against votes; all proposals pass","event_type":"other","sec_items":["5.07","8.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215591","json":"https://secwatch.observer/filing/0001193125-26-215591.json","markdown":"https://secwatch.observer/filing/0001193125-26-215591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393311/000119312526215591/0001193125-26-215591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393311/000119312526215591/d138131d8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"3. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 as follows: Votes For Votes Against Abstain Broker Non-Votes 153,317,363 10,957,104 59,863 —","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1393311/000119312526215591/0001193125-26-215591-index.htm"}},{"accession":"0001104659-26-068996","ticker":"XBP","company_name":"XBP Global Holdings, Inc.","filed_at":"2026-06-01T21:00:49+00:00","headline":"XBP Global Holdings annual meeting elects directors, approves auditor and say-on-pay","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068996","json":"https://secwatch.observer/filing/0001104659-26-068996.json","markdown":"https://secwatch.observer/filing/0001104659-26-068996.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/0001104659-26-068996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/tm2616124d2_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"· Proposal 3 — To consider and vote upon a proposal to approve, on an advisory (non-binding) basis, the compensation of our named executive officers (the “say-on-pay vote”): Votes For Votes Against Votes Abstained Broker Non-Votes 8,208,462 1,323,885 1,011 577,920","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/0001104659-26-068996-index.htm"}},{"accession":"0001193125-26-251689","ticker":"SCHW","company_name":"SCHWAB CHARLES CORP","filed_at":"2026-06-01T21:00:25+00:00","headline":"Charles Schwab files Certificate of Elimination for Series I Preferred Stock","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251689","json":"https://secwatch.observer/filing/0001193125-26-251689.json","markdown":"https://secwatch.observer/filing/0001193125-26-251689.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/0001193125-26-251689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/d143555d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"On June 1, 2026, The Charles Schwab Corporation (the “Company”) filed a Certificate of Elimination with the Secretary of State of the State of Delaware with respect to the Company’s 4.000% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series I (“Series I Preferred Stock”), which, effective upon filing, eliminated from the Company’s Fifth Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series I Preferred Stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/0001193125-26-251689-index.htm"}},{"accession":"0001628280-26-039483","ticker":"AXON","company_name":"AXON ENTERPRISE, INC.","filed_at":"2026-06-01T20:10:40+00:00","headline":"Axon shareholders elect all 9 director nominees and approve say-on-pay at 2026 annual meeting","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039483","json":"https://secwatch.observer/filing/0001628280-26-039483.json","markdown":"https://secwatch.observer/filing/0001628280-26-039483.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/0001628280-26-039483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/axon-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"The non-binding advisory vote to approve the compensation of the Company's named executive officers was approved as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 54,903,698 6,239,017 112,972 11,665,236","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/0001628280-26-039483-index.htm"}},{"accession":"0001828536-26-000052","ticker":"NRGV","company_name":"Energy Vault Holdings, Inc.","filed_at":"2026-06-01T15:36:32+00:00","headline":"Energy Vault shareholders elect three Class II directors and ratify BDO USA as auditor","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001828536-26-000052","json":"https://secwatch.observer/filing/0001828536-26-000052.json","markdown":"https://secwatch.observer/filing/0001828536-26-000052.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828536/000182853626000052/0001828536-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828536/000182853626000052/nrgv-20260529.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"Proposal 2 - Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Votes Abstaining Broker Non-Votes 127,775,985 168,810 59,341 —","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1828536/000182853626000052/0001828536-26-000052-index.htm"}},{"accession":"0000089089-26-000046","ticker":"SCI","company_name":"SERVICE CORP INTERNATIONAL","filed_at":"2026-05-08T23:59:59+00:00","headline":"SCI shareholders approve board governance changes: director minimum cut to 3, board can fill vacancies","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0000089089-26-000046","json":"https://secwatch.observer/filing/0000089089-26-000046.json","markdown":"https://secwatch.observer/filing/0000089089-26-000046.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/89089/000008908926000046/0000089089-26-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/89089/000008908926000046/sci-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm","comparable_excerpt":"The amendments to the Articles of Incorporation, which became effective on May 7, 2026, and the amendments to the Bylaws, which became effective on May 6, 2026 , include (i) changes permitting the Board to increase the number of directors and fill newly created vacancies, thereby eliminating restrictions requiring that newly created directorships be filled only by shareholders at an annual or special meeting, and (ii) changes reducing the minimum number of directors constituting the Board from nine to three directors (with the maximum remaining at fifteen directors).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/89089/000008908926000046/0000089089-26-000046-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}